|
1) Ogishima T, Shibata H, Shimada H, et al. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem. 1991; 266: 10731-4
|
|
|
|
2) Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab. 2010; 95: 2296-305
|
|
|
|
|
3) Nishimoto K, Nakagawa K, Oya M, et al. Pathological confirmatory diagnosis of primary aldosteronism. Endocr Surg. 2010; 27: 241-7
|
|
|
|
|
|
4) Ogishima T, Suzuki H, Hata J, et al. Zone-specific expression of aldosterone synthase cytochrome P-450 and cytochrome P-45011 beta in rat adrenal cortex: histochemical basis for the functional zonation. Endocrinology. 1992; 130: 2971-7
|
|
|
|
|
|
5) Mitani F, Suzuki H, Hata J, et al. A novel cell layer without corticosteroid-synthesizing enzymes in rat adrenal cortex: histochemical detection and possible physiological role. Endocrinology. 1994; 135: 431-8
|
|
|
|
|
|
6) Boulkroun S, Samson-Couterie B, Golib-Dzib J-F, et al. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology. 2011; 152: 4753-63
|
|
|
|
|
|
7) Doi M, Takahashi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian cock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 2010; 16: 67-75
|
|
|
|
|
|
8) Rossier BC. Hypertension finds a new rhythm. Nat Mad. 2010; 16: 27-8
|
|
|
|
|
|
9) Rosmond R, Chagnon M, Bouchard C, et al. Polymorphism in exon 4 of the human 3β-hydroxysteroid dehydrogenase type I gene (HSD3B1) and blood pressure. Biochem Biophys Res Commun. 2002; 293: 629-32
|
|
|
|
|
|
10) Shimodaira M, Nakayama T, Sato N, et al. Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure. Eur J Endocrinol. 2010; 163: 671-80
|
|
|
|
|
|
11) Hattangady NG, Olala LO, Bollag WB, et al. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2011; August 4 epub ahead of print
|
|
|
|
|
|
12) Demura M, Wang F, Yoneda T, et al. Multiple noncoding exons 1 of nuclear receptors NR4A family (nerve growth factor-induced clone B, Nur-related factor 1 and neuron-derived orphan receptor 1) and NR5A1 (steroidogenic factor 1) in human cardiovascular and adrenal tissues. J Hypertens. 2011; 29: 1185-95
|
|
|
|
|
|
13) Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary aldosteronism. Circulation. 2011; 124: 1945-55
|
|
|
|
|
|
14) Choi M, Scholl UI, Yue P, et al. K＋ channel mutations in adrenal aldosterone-producing adenomas and hereditray hypertension. Science. 2011; 331: 768-72
|
|
|
|
|
|
15) Funder JW. The genetics of primary aldosteronism. Science. 2011; 331: 685-6
|
|
|
|
|
|
16) Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-The Japan Endocrine Society 2009-. Endocr J. 2011; 58: 7111-721
|
|
|
|
|
|
17) Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266-81
|
|
|
|
|
|
18) Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol. 2011; 7: 485-95
|
|
|
|
|
|
19) Auchus RJ. Primary aldosteronism and a Texas two-step. Rev Endocr Metab Disord. 2011; 12: 37-42
|
|
|
|
|
|
20) Karagiannis A. Treatment of primary aldosteronism: where are we now？ Rev Endocr Metab Disord. 2011; 12: 15-20
|
|
|
|
|
|
21) Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin N Am. 2011; 40: 333-41
|
|
|
|
|
|
22) Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring non-glucocorticoid-remediable aldosteornism. J Clin Endocrinol Metab. 2008; 93: 3117-23
|
|
|
|
|
|
23) Quack I, Vonend O, Rump LC. Familial hyperaldosteronism I-III. Horm Metab Res. 2010; 42: 424-8
|
|
|
|
|
|
24) Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in Torino-GENetic forms). Hypertension. 2011; 58: 797-803
|
|
|
|
|
|
25) Stowasser M, gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol. 2001; 28: 1087-90
|
|
|
|
|
|
26) Heitzmann D, Derand R, Jungbauer S, et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J. 2008; 27: 179-87
|
|
|
|
|
|
27) Davies LA, Hu C, Guagliardo NA, et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc Natl Acad Sci U S A. 2008; 105: 2203-8
|
|
|
|
|